Excerpt: Darwinism and Design – Discovery Institute

Editors note: We are delighted to celebrate the publication of the new book A Mousetrap for Darwin: Michael J. Behe Answers His Critics. What follows is an excerpt. Darwinism and Design was published originally as a letter to the editor in Trends in Ecology and Evolution 12, No. 6 (June 1997): 229.

Authors note: One of the earliest reviews of my book Darwins Black Box was by Oxford evolutionary biologist Tom Cavalier-Smith. I had discussed some of his musings rather unfavorably in the book, and he returned the favor in the review.

In his review of my book Darwins Black Box, which is critical of Darwinian theory, Tom Cavalier-Smith alternates between calling me ignorant and calling me deceitful, but finally seems to conclude that I am intentionally dishonest because of my religious views. I do not wish to descend into acrimony, so let me state plainly that my religious convictions can easily accommodate a Darwinian explanation for life, and I said so in my book. I have no motive, religious or otherwise, to be dishonest. I wrote the book (which I knew would be controversial) out of a straightforward, professional conviction that many complex biochemical systems are beyond Darwinian explanation.

Well, I am not dishonest, but am I ignorant? Perhaps so. No one can be completely in command of the literature, and I would be very happy to be shown citations to published work explaining in detail how complex biochemical systems evolved by natural selection. However, Professor Cavalier-Smith says there is no such work: For none of the cases mentioned by Behe is there yet a comprehensive and detailed explanation of the probable steps in the evolution of the observed complexity. The problems have indeed been sorely neglected. Yet he thinks that, even if detailed explanations are unavailable, general explanations are in hand. He cites ten references in his review. Of the ten, half refer to his own work, only four are published in this decade, and only two are reports of original research. From my point of view, in all of the cited papers the evolutionary explanation takes the form System X developed because it would help the cell to do Y, without noticing the difficulties of making X by a blind process. Its like saying, Air conditioners developed to enable more people to work indoors in the summertime.

Much of the difficulty arises in the differing standards that different disciplines have for what constitutes an explanation. Biochemists require molecular detail. Cavalier-Smith, however, does not. (Indeed, he even castigates Trends in Biochemical Sciences for noticing engineering design in biochemical systems.) Darwinian evolution, though, would necessarily have to take place at the nut-and-bolt molecular level, the domain of biochemistry. A Darwinian evolutionary explanation, therefore, has to be a detailed biochemical explanation. None currently exist. By itself this fact doesnt justify the conclusion of intelligent design that I reach. (I also advance other arguments for design in my book.) But by itself the absence of detailed Darwinian explanations should provoke more thoughtfulness than was shown in Cavalier-Smiths review.

Read the original post:

Excerpt: Darwinism and Design - Discovery Institute

Darwin’s Finches: Galpagos Islands as an Evolutionary Model – Discovery Institute

Photo: Medium tree finch, by Jody O'Connor, Public domain, via Wikimedia Commons.

Authors note: Are Darwins finchesa particularly compelling example of speciation as well as evolution in action? In a series of posts, I have offered some notes on the question of whether macroevolution is happening on the Galpagos Islands.Please find the full series here.

Taking the facts and arguments presented together, it appears to be clear that no macroevolution is happening in Darwins finches on the Galpagos Islands.

The following is the English translation of some especially relevant and up-to-date points from a discussion1with Professor Dr. Reinhard W. Kaplan 1991. He was the director of the Institute of Microbiology (Lehrstuhl fr Mikrobiologie) at the Johann Wolfgang von Goethe Universitt, Frankfurt am Main2. He did not continue the discussion.

Evolution on an isolated island like the Galpagos,

The evolution on the Galpagos Islands is one of the best examples against the model favored by Prof. K. Because starting from the isolated island, the new founder populations should grow rapidly, continuously add beneficial hereditary changes, quickly displace their original populations and thereby become large populations themselves. It is now just one of the more recent significant biological discoveries thatisland populations do not meet the criteria (which are decisive for the question of the correctness of neo-Darwinism) fordisplacement of the original populations and expansion into large populations. In this context I refer to the excellent monograph by J. A. Drake et al. (1989), Biological Invasions(Wiley, Chichester, New York).

Would it really occur to anyone that the Galpagos finches might conquer mainland South America, displace populations there, and, if transferred to southern Europe and Africa, spread in the same way as, e.g., the European house sparrows in North America?

It is exactly the other way around: the island populations must be protected from invasion by widespread continental species! Braun reports (1989, p. 86) empirically derived rules for this question, for example: Isolated environments with a low diversity of native species tend to be differentially susceptible to invasion. species that are successful invaders tend to be native to continents and to extensive, non-isolated habitats within continents (p. 92). The fact thatthere are almost no good examples of successful invaders of continents that have come from small islandsand other depauperate faunas suggests that biotic resistance from diverse native species can be effective in repelling invaders (p. 96) (emphasis added, here as in quotations throughout this post).

Macdonald et al. 1989, p. 234: Although only a small percentage of the worlds land and freshwater avifauna occurs on oceanic islands93% of the 93 species and 83 subspecies of birds that have become extinct since 1600 AD have been island forms (King, 1985).

Honegger (1981, p. 235) lists two amphibians and 28 reptile taxa known to have become extinct since 1600 AD.The reptiles were all island forms and introduced species are implicated in the extinction of at least eight of them and one of the two amphibians.

Loope et al. 1989, p. 272: The rigor of natural selection in such an evolving insular system may be relaxed by a large number of bottle necks (founder events) many groups have undergone in island hopping. in many instances (the island forms)may not be so well adapted as the general purpose genotypes of invasive introduced species.

Pimm 1989, p. 355: Species with larger ranges were more likely to be successful than species with smaller ranges. Many introductions will succeed only if their numbers can increase quickly, beyond the small population size where extinction is likely. The same author on p. 352: The chance of extinction rapidly increases as population sizes decrease.Even in a perfectly constant environment, small populations face risk of extinction from demographic accidentsthe chance fluctuations of deaths and births, and consequent changes of numbers and sex ratios.Another risk of becoming extinct is a low rate of population growth.

The latter observations are particularly informative for the question of the evolution of species in small populations in 100,000 to 10,000,000 years (see Prof. K. above). The postulated macroevolution is unlikely for demographic and genetic reasons and can therefore not be accepted as a general rule for the origin of species.

Other authors have come to similar conclusions. Wills (1990, p. 398) discusses the problem in connection with mitochondrial Eva and an average population size of 5,000 women: Such small sizes would have to be maintained for thousands of yearswith an attendant risk of extinction. And he makes the following comparison: The risk posed to the survival of the population in [this] case isequivalent to the risk of crossing the Niagara Falls on a tightrope.

Rabb and Lacy 1990, p. 612, on the topic of endangered-species biology:

Genetic homogeneity can imperil a species, but such inbreeding occurs as a consequence of population decline and fragmentation. It is just one of several interacting factors that come into play when a population becomes so small that its fate is determined more by randomness than by fitness. Once populations are reduced and isolated, deleterious genetic and demographic factors ensue that serve to weaken further the survival of the species. The smaller populations also become progressively more vulnerable to environmental catastrophes. Even with amelioration of environmental circumstances, for example, provision of security in protected areas or zoological parks a species may go too far down the so-called extinction vortex of multiple causes to be recoverable.

Small populations over large numbers of generations with many recessive mutations are thereforean extremely unfavorable starting point for explaining the sudden appearance of Cambrian and other life forms and the fact that the temporal maxima of the construction plans and higher systematic categories occur before the lower ones!

With populations of approximately 10,000 individuals (see above: 5,000 women) and 1 million generations, 10 billion individuals would have been necessary for speciation. Was there really no chance of fossilization? The geologists Bennison and Wright, following the work of Shaw,calculate an average of 1 fossil per 1 million individuals! Even Galpagos finches have been found in fossil form! (See Grant 1984). And what about foraminifera, corals, brachiopods, cephalopods, etc., which are so well documented?

Galpagos, where Darwin received inspiration for his theory.

According to several historians of science, this is a myth. Darwin was only made aware of the differences in, e.g.,Mimus species by ornithologist John Gould after his return to England. In retrospect, he [Darwin] was astonished at what he saw there (Berry 1984, p. 1).

The following from Sull0ways paper (1982, pp. 57-58) on TheBeagleCollections of Darwins Finches(Geospizinae)3and my subsequent comment are an addition made September 23, 2020 (the footnotes are Sulliways):

The celebrated ornithologist John Gould, who was closely associated with the Zoological Society, lost no time in examining and naming the unusual finches that Darwin had brought back from the Galpagos Islands. At the very next meeting of the society (10 January), Gould described these birds as twelve new species, which he placed in one genus and two closely allied subgenera (Geospiza,Cactornis, andCamarhynchus). Moreover, he astutely realized the basic peculiarity of these finches, namely, that thebill appears to form only a secondary character. Soon afterwards Gould recognizedCerthidea olivacea, the Warbler Finch, as a thirteenth species of the group, belonging to yet another genus16.

Darwin, who was at this time residing in Cambridge, did not learn of the details of Goulds analysis until he moved to London in early March of 1837 in order to have closer contact with the specialists working on his collections. Goulds findings, communicated to Darwin during a meeting with the eminent ornithologist,provided Darwin with a number of surprises17.While in theGalpagos, Darwin had been rather unclear about the precise relationship among the various finchlike species he had encountered there. In particular, he had misidentified several finch species as the forms that they, through extensive evolutionary radiation, now appear to mimic. For example, he had considered theCactus Finch,Cactornis scandens, to be a member of the Icteridae (the family of the orioles and blackbirds); and he had classified the Warbler Finch,Certhidea olivacea, as a wren, or warbler. It appears, moreover, that Darwin initially distinguished as separate species of finches only 6 of the eventual 13 forms that Gould named in early 1837.Hence Darwins finches only really became Darwinsfinchesafter Gould rectified many of Darwins earlier field misclassifications, and thereby clarified the unity and complexity of the group18. More important still for Darwins evolutionary thinking, Gould (1837d) declared that 3 of the 4 island forms ofGalpagosmockingbird brought to England by Darwin were distinct species, a possibility that Darwin had already asserted would undermine the stability of Species. For the Galpagosas a whole, Gould pronounced 25 of the 26 land birds as new and distinct forms found nowhere else in the world.Darwin was frankly stunned, not only by the realization that three separate species of mockingbirds indeed inhabited the different islands of the Galpagos, but also by the fact that most of these Galpagosspecies, even though new, were closely related to those found on the American continent19. His conversion to the theory of evolution, which took place shortly after his meeting with Gould in March of 1837, was a direct consequence of these two conclusions.

This conversion constitutes, in fact, an astonishing confusion and misunderstanding of the morphological species concept (cf.here) by Darwin as well as Sulloway.

This branching out (typogenesis) usually happens relatively quickly, as the pace of evolution is usually high during adjustment to new niches (ways of life).

Typogenesis did not take place in the Galpagos! Even the formation of species in the finches is still doubtful: Intersterility is not known in Darwins finches. Intrageneric hybrids among ground finches are certainly both viable and fertile and probably the same is true for intergeneric hybrids between tree finches and warbler finches (Grant 1986, p. 353). [S]ix species of Geospizina (finches) in the Galpagos Islands show a genetic distance from 0.004 to 0.065 (Nei 1987, p. 245). In humans, the differences are between 0.01 and 0.03. The small genetic distances of islanders are in clear contrast to the morphological differences that we also find in domestic animals. (These are further proofs that morphological and genetic distances need not be coupled with each other.)

Nei continues:

With domestic animals one normally refrains from establishing new systematic species and genera, in nature, however, one creates numerous morphospecies and morphogenera, regardless of the genetic situation, which are often used uncritically as evidence of evolution.

In their study, Loop et al. (1989, pp. 271-272) pointed to the general trend of little genetic distance between morphologically and ecologically strongly diverging (but closely related) island species. In the HawaiianTetramolopium(Asteraceae), for example, Lowry and Crawford examined 19 populations of 7 species: The mean genetic identity for pairwise comparisonis 0.95, a very high value normally obtained for conspecific plant populations.'

TheflightlessGalpagoscormorants clearly illustrate the degeneration of structures, a process that seems to occur rather quickly in small populations through inbreeding involving homozygous occurrence of numerous recessive alleles (already accumulated in previous larger populations).

What we detecthere is not typogenesis, but typolysis! This also explains the low resistance of island populations to invaders and the high rate of extinction.

The comparison with domestic animals illustrates the situation in several aspects. In both groups we find:

Conclusion: No explanation of the paleontological findings (among others)!

If a niche has been occupied for a long time by a species that fully utilizes it, rich in individuals, progressive hereditary variants are rare for a long time, and evolution seems to stagnate (typostasis). If adverse environmental changes are not absorbed (buffered) by hereditary variants resistant to them, the population will die out.

Since the species with a large number of individuals, due to the recurrent mutations that occur regularly, must have a significantly greater allelic potential than a small population, it is questionable why the former may have unfavorable environmental conditions to which they cannot not adapt, while the individual poor population with low genetic potential (see above) should be capable of rapid evolution! As a rule,the widespread specieswith its much greater genetic potential should be able to adapt to the new conditions in many places at the same time through allele substitution and thusshould have better chances of survival than the small population with its few possibilities in the same situation which, as we have seen is, in fact, the case.

According to the theory, the pace of evolution can vary from (geologically) fast to slow, depending on the circumstances.

Since the term evolution implies the origin of all forms of life, it should be noted here that Prof. K.s theory cannot explain the origin of the primary species or the higher systematic categories and Bauplne. According to the available findings, it is the pace of degeneration that can vary rapidly to slowly, depending on the circumstances geologically.

For a full presentation of this series including supplements, please see my Internet Library here.

Go here to see the original:

Darwin's Finches: Galpagos Islands as an Evolutionary Model - Discovery Institute

Medical history from the year you were born – Quad City Times

Medicine is ever-evolving on a daily basis. Keeping track of the changes can be an almost-full-time job.Stacker looked at a number of medical journals and media sources to discover the biggest breakthroughs the year you were born, from 1921 to the current day.

From diseases that have been around for decades, such as diabetes and the flu, to cutting-edge tools like artificial intelligence and 3D printing, explore how medical and scientific professionals continually conduct research and clinical trials to improve the lives of patients. Sometimes advances arent immediately adopted, as with the Pap smearthat wasnt integrated into womens health care for 16 years after it was invented. But other times the path from laboratory to everyday use is much more abbreviated, like with insulin, which was used to treat diabetes only a year after it was discovered.

Another recurring theme in medical history is the repurposing of medicines that have worked for one disease in the past, to see how theyll work with another. A number of drugs and vaccines are being re-explored to manage COVID-19. Not all the heroes of medical research come from a traditional backgroundone was an electric engineer who worked for a major record label. Some were recognized with the highest honors, but others still have little visibility decades after their death. Funding for the research behind the breakthroughs is always a considerationsometimes it comes from foundations and government entities, but other times via donations from individuals and enterprises.

The dark side of medical history shown here includes unethical behavior by researchers in the past, which explains why some in the Black community arent exactly early adopters when it comes to clinical trials and new treatment options.

Advances noted here focus not only on the body, but also the mind. Explore this slideshow to see all the ways that health care has changed over the past century.

You may also like: Countries with the best life expectancy

See the original post:

Medical history from the year you were born - Quad City Times

Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy – GlobeNewswire

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020 at 8:30 am Eastern Time (ET), it will host a webcast and conference call to present interim data from the MOMENTUM study, a multiple-ascending dose clinical trial of SRP-5051 for the treatment of Duchenne muscular dystrophy. SRP-5051 is the first investigational treatment using Sareptas next-generation PPMO platform, which is designed around a proprietary cell-penetrating peptide conjugated to Sareptas phosphorodiamidate morpholino oligomer (PMO) backbone with the goal of increasing drug concentration in muscle tissue.

The presentation will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and slides will be archived there following the call for one year. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 6382259. Please specify to the operator that you would like to join the "Sarepta-hosted Clinical Update for MOMENTUM call."

AboutSarepta Therapeutics At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.com

Media: Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com

Read more:

Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy - GlobeNewswire

December: Baby birth weight research | News and features – University of Bristol

Genetics of mother and baby contribute to most cases where babies are born very large or very small, according to new research.

Genetics of mother and baby contribute to most cases where babies are born very large or very small, according to new research.

A large scale study, led by the University of Exeter and Cardiff University, has found the strongest evidence to date that genetics play a major role in most cases when babies born at full term are in the top or bottom 10 per cent of the weight spectrum.

However, in the three per cent of babies with the smallest birth weights, genetics seemed to play a less important role. This indicated that other factors may be contributing to the babies small size. The research looked at 190 common genetic variations that are known to affect birth weight, yet it is possible that rare genetic changes in the baby reduce growth in the smallest three per cent. Other important factors could include the health of the mother or fetus or of the placenta, which transfers nutrients and oxygen to the baby.

The study was a collaboration also involving the University of Bristols Children of the 90s, Imperial College London, and the University of Oulu in Finland. The research was supported by Wellcome Trust and the H2020 program of the European Commission.

The weight of babies at birth is important, as those born at the extreme ends are at higher risk of complications. Smaller babies are more likely to be admitted to neonatal units and at higher risk of death, while larger babies are at higher risk of complications during birth.

To examine the extent to which birth weight was linked to the genetics of mothers and babies, the team created a genetic score for higher birth weight. Published today in PLOS Genetics, the study tested whether the genetic score was higher or lower in babies who were born very large or very small in a sample of nearly 12,000 babies and more than 5,000 mothers of European ancestry. The mothers and babies were from Children of the 90s, a health study based at the University of Bristol, the Exeter Family Study of Childhood Health and the Northern Finland Birth Cohorts 1966 and 1986.

Dr Robin Beaumont, of the University of Exeter Medical School, was lead author of the study. He said: This research casts new light on why some babies are born very large or small. This knowledge will help both parents and clinicians understand where they need to focus medical attention. Genetics played a lesser role in the three per cent of babies with the lowest weight, suggesting that other factors such as the health of the placenta, may have influenced their weight.

Co-lead author and clinician, Professor Sailesh Kotecha, of Cardiff University, added: Its important to identify reasons why babies are born with low birth weight as they are at risk of increased health problems in later life including diabetes and high blood pressure. Our work shows that genetics are a key part of the reason why some babies are born small, and raises the possibility that genetics could be used alongside maternal and placental factors to identify those most likely to have fallen short of their growth potential.

Professor Rachel Freathy, of the University of Exeter, who oversaw of the study said: Our study gives the greatest insight to date into how common genetic variations between people influence the extremes of birth weight. We now need to understand better whether the genetics or environmental factors are more important in the later life health risks.

The paper is entitled Common maternal and fetal genetic variants show expected polygenic effects on risk of small- or large-for-gestational-age (SGA or LGA), except in the smallest 3% of babies, and is published in PLOS Genetics.

The paper is entitled Common maternal and fetal genetic variants show expected polygenic effects on risk of small- or large-for-gestational-age (SGA or LGA), except in the smallest 3% of babies, and is published inPLOS Genetics.

About the University of Exeter Medical School

The University of Exeter Medical School is part of the University of Exeters College of Medicine and Health. Our mission is to improve the health of the South West and beyond, through the development of high quality graduates and world-leading research that has international impact.

As part of a Russell Group university, we combine this world-class research with very high levels of student satisfaction. Exeter has over 19,000 students and is ranked 12th in The Times and Sunday Times Good University Guide 2020.

The University of Exeter Medical Schools Medicine course is in the top 10 in the Complete University Guide 2020.

The Colleges Medical Imaging programme is ranked in the top 5 in the Guardian Guide 2020 and the Complete University Guide 2020.

The University of Exeter entered the world top 20 for Biomedical and Health Sciences in the CWTS Leiden Ranking 2019, based on the percentage of publications ranked in the top 10 per cent most cited.

https://medicine.exeter.ac.uk/

Cardiff University is recognised in independent government assessments as one of Britains leading teaching and research universities and is a member of the Russell Group of the UKs most research intensive universities. The 2014 Research Excellence Framework ranked the University 5th in the UK for research excellence. Among its academic staff are two Nobel Laureates, including the winner of the 2007 Nobel Prize for Medicine, Professor Sir Martin Evans. Founded by Royal Charter in 1883, today the University combines impressive modern facilities and a dynamic approach to teaching and research. The Universitys breadth of expertise encompasses: the College of Arts, Humanities and Social Sciences; the College of Biomedical and Life Sciences; and the College of Physical Sciences and Engineering, along with a longstanding commitment to lifelong learning. Cardiffs flagship Research Institutes are offering radical new approaches to pressing global problems. More atwww.cardiff.ac.uk

About Children of the 90s

Based at the University of Bristol, Children of the 90s, also known as the Avon Longitudinal Study of Parents and Children (ALSPAC), is a long-term health-research project that enrolled more than 14,000 pregnant women in 1991 and 1992. It has been following the health and development of the parents and their children in detail ever since and is currently recruiting the children and the siblings of the original children into the study. It receives core funding from the Medical Research Council, the Wellcome Trust and the University of Bristol. Find out more at http://www.childrenofthe90s.ac.uk

Read the original:

December: Baby birth weight research | News and features - University of Bristol

Biochip Market | Increased Popularity of Personalized Medicine to Boost the Market Growth | Technavio – Business Wire

LONDON--(BUSINESS WIRE)--The global biochip market size is poised to grow by USD 19.71 billion during 2020-2024, progressing at a CAGR of 22% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

Personalized medicines growing popularity and demand is expected to drive the growth of the Biochip market. The medicines are personalized as per the patients needs which suits the individual characteristics of the person is a multi-faceted approach. This improves the ability to diagnose and effectively treat the disease as this technique facilitates early diagnosis. These biochips play an important part in the development of these medicines, as it improves the ability to diagnose and effectively treat the disease. It is also expected that during the forecast period the growing incidences of genetic and terminal diseases will influence the demand for personalized medicine for targeted drug development. This will increase the demand for biochips which will result in the growth of this industry.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Report Highlights:

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Rising Use of Biochips in Safety Detection of Agriculture Products will be a Key Market Trend

The rising use of biochip technology in the agriculture industry is turning out to be one of the major trends in the biochip industry. Biochip helps in the detection of pathogenic microorganisms, biological toxins, pesticide residues, and antibiotics. Microchips help in providing early warning to agricultural products' monitoring with a rapid response system and, thus, enhance the agricultural products' safety detection system. Therefore, significantly helping the agriculture industry from the loss it faces every year.

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Biochip Market 2020-2024: Key Highlights

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

See the original post here:

Biochip Market | Increased Popularity of Personalized Medicine to Boost the Market Growth | Technavio - Business Wire

NIH researchers link cases of ALS and FTD to a mutation associated with Huntington’s disease – National Institute on Aging

A study led by researchers at the National Institutes of Health has made a surprising connection between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two disorders of the nervous system, and the genetic mutation normally understood to cause Huntingtons disease.

This large, international project, which included a collaboration between the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), opens a potentially new avenue for diagnosing and treating some individuals with FTD or ALS.

Several neurological disorders have been linked to repeat expansion, a type of mutation that results in abnormal repetition of certain DNA building blocks. For example, Huntingtons disease occurs when a sequence of three DNA building blocks that make up the gene for a protein called huntingtin repeats many more times than normal. These repeats can be used to predict whether someone will develop the illness and even when their symptoms are likely to appear, because the more repeats in the gene, the earlier the onset of disease.

It has been recognized for some time that repeat expansion mutations can give rise to neurological disorders, said Sonja Scholz, M.D., Ph.D., investigator, NINDS Intramural Research Program. But screening for these mutations throughout the entire genome has traditionally been cost-prohibitive and technically challenging.

Taking advantage of technology available at NIH, the researchers screened the entire genomes from large cohorts of FTD/ALS patients and compared them to those of age-matched healthy individuals. While several patients had a well-established genetic marker for FTD/ALS, a small subset surprisingly had the same huntingtin mutation normally associated with Huntingtons disease. Remarkably, these individuals did not show the classical symptoms of Huntingtons but rather those of ALS or FTD.

None of these patients symptoms would have clued their physicians into thinking that the underlying genetic cause was related to the repeat expansion we see in Huntingtons disease, said Dr. Scholz.

She continued by explaining that whole-genome sequencing is changing how neurological patients can be diagnosed. Traditionally, this has been based on which disease best fit the overall symptoms with treatment aimed at managing those symptoms as best as possible. Now, clinicians can generate genetically defined diagnoses for individual patients, and these do not always align with established symptom-based neurological conditions.

Our patients simply dont match a textbook definition of disease when it comes to which mutation produces which symptoms. Here we have patients carrying a pathogenic huntingtin mutation but who present with FTD or ALS symptoms, said Dr. Scholz.

One implication of these findings is that, if successful, these therapies could be applied to the small subset of FTD and ALS patients with that mutation as well. The researchers note that, although the number of FTD/ALS patients seen with the Huntingtons-linked mutation is small (roughly 0.12-0.14%), adding genetic screening for the mutation to the standard diagnostic procedure for patients showing symptoms of FTD or ALS should be considered.

Because gene therapy targeting this mutation is already in advanced clinical trials, our work offers real hope to the small number of FTD and ALS patients who carry this mutation, said Bryan Traynor, M.D., Ph.D., senior investigator, NIA Intramural Research Program. This type of large-scale international effort showcases the power of genomics in identifying the molecular causes of neurodegenerative diseases and paves the way for personalized medicine.

Reference: Dewan R, et al. Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. Neuron. 2020. ePub Nov. 25. doi: 10.1016/j.neuron.2020.11.005.

About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIAs Alzheimer's and related Dementias Education and Referral (ADEAR) Center website. For information about a broad range of aging topics, visit the main NIA website and stay connected.

About National Institute of Neurological Diseases and Stroke (NINDS): NINDS is the nations leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit the NIH website.

NIH...Turning Discovery Into Health

###

Read more from the original source:

NIH researchers link cases of ALS and FTD to a mutation associated with Huntington's disease - National Institute on Aging

Global Next Generation Sequencing Market (2020 to 2026) – Growth, Trends, Competitive Landscape, and Forecasts – GlobeNewswire

Dublin, Dec. 03, 2020 (GLOBE NEWSWIRE) -- The "Global Next Generation Sequencing Market: Growth, Trends, Competitive Landscape, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The global next-generation sequencing market is expected to grow at a CAGR of around 17.5% during 2020-2026. Next-generation sequencing is also known as high-throughput sequencing. It is the process of determining the sequence of nucleotides in a section of the DNA. It includes procedures such as sequencing by ion semiconductor sequencing, synthesis (SBS), nanopore sequencing and single-molecule real-time (SMRT) sequencing. It is a cost-effective solution that offers precise results with high accuracy and speed. This enables the analysis of millions of DNA molecules simultaneously, which facilitates research in the fields of personalized and genetic medicines, agriculture and animal research, and clinical diagnostics.

Market Drivers

Market Challenges

Report's Scope

The global next-generation sequencing market report elucidates key industry trends, industry dynamics along with the quantitative analysis of the report. The report presents a clear picture of the global next-generation sequencing market by segmenting the market based on sequencing type, product type, technology, application, end user, and region. We believe that this report will aid the professionals and industry stakeholders in making informed decision.

Key Topics Covered:

1. Preface1.1 Report Description1.1.1 Objective of the Study1.1.2 Target Audience1.1.3 USP & Key Offerings1.2 Report's Scope1.3 Research Methodology1.3.1 Phase I - Secondary Research1.3.2 Phase II - Primary Research1.3.3 Phase III - Expert Interviews1.3.4 Assumptions

2. Executive Summary

3. Global Next Generation Sequencing Market3.1 Introduction3.2 Market Drivers & Challenges

4. Global Next Generation Sequencing Market Analysis4.1 Market Portraiture4.2 Market by Sequencing Type4.3 Market by Product Type4.4 Market by Technology4.5 Market by Application 4.6 Market by End User4.7 Market by Region 4.8 Impact of COVID-19

5. Global Next Generation Sequencing Market by Sequencing Type 5.1 Market Overview5.2 Whole Genome Sequencing5.3 Targeted Resequencing5.4 Whole Exome Sequencing5.5 RNA Sequencing5.6 CHIP Sequencing5.7 De Novo Sequencing5.8 Methyl Sequencing5.9 Others

6. Global Next Generation Sequencing Market by Product Type 6.1 Market Overview6.2 Instruments6.3 Reagents and Consumables6.4 Software and Services6.5 Others

7. Global Next Generation Sequencing Market by Technology Type 7.1 Market Overview7.2 Sequencing by Synthesis7.3 Ion Semiconductor Sequencing7.4 Single-Molecule Real-Time Sequencing7.5 Nanopore Sequencing7.6 Others

8. Global Next Generation Sequencing Market by Application8.1 Market Overview8.2 Drug Discovery and Personalized Medicine8.3 Genetic Screening8.4 Diagnostics8.5 Agriculture and Animal Research8.6 Bioinformatics8.7 Others

9. Global Next Generation Sequencing Market by End User9.1 Market Overview9.2 Academic Institutes & Research Centers9.3 Hospitals & Clinics9.4 Pharmaceutical & Biotechnology Companies9.5 Others

10. Global Next Generation Sequencing Market by Region10.1 Market Overview10.2 Europe10.2.1 Germany10.2.2 United Kingdom10.2.3 France10.2.4 Italy10.2.5 Spain10.2.6 Netherlands10.2.7 Russia10.2.8 Rest of the Europe10.3 North America10.3.1 United States10.3.2 Canada10.4 Asia Pacific10.4.1 China10.4.2 Japan10.4.3 South Korea10.4.4 Australia10.4.5 India10.4.6 Indonesia10.4.7 Rest of the Asia Pacific10.5 Latin America10.5.1 Mexico10.5.2 Brazil10.5.3 Argentina10.5.4 Rest of Latin America10.6 Middle East & Africa10.6.1 Saudi Arabia10.6.2 Turkey10.6.3 United Arab Emirates10.6.4 Rest of Middle East & Africa

11. SWOT Analysis

12. Porter's Five Forces

13. Market Value Chain Analysis

14. Competitive Landscape14.1 Competitive Scenario14.2 Company Profiles14.2.1 10x Genomics14.2.2 Agilent Technologies Inc.14.2.3 Becton Dickinson and Company14.2.4 BGI Group14.2.5 Eurofins Scientific14.2.6 F. Hoffmann-La Roche AG14.2.7 Illumina Inc.14.2.8 Genewiz14.2.9 Macrogen Inc.14.2.10 Oxford Nanopore Technologies14.2.11 Pacific Biosciences14.2.12 Perkinelmer Inc.14.2.13 Thermo Fisher Scientific Inc.14.2.14 Qiagen N.V.14.2.15 Genapsys Inc.

For more information about this report visit https://www.researchandmarkets.com/r/j561mc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Go here to read the rest:

Global Next Generation Sequencing Market (2020 to 2026) - Growth, Trends, Competitive Landscape, and Forecasts - GlobeNewswire

Precision Medicine Market Poised to Grow at 11.5% By 20227 – GlobeNewswire

OTTAWA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- The global precision medicine market value surpassed USD 59.16 billion in 2019 and expected to reach USD 141.33 billion by 2027.

Precision medicine is an emerging approach of treatment and prevention of disease that takes into account the individual variability in environment, genes, and lifestyle for each person. This approach allows researchers and doctors to predict more precisely that which treatment and prevention strategies for a particular disease will work on the specified groups of people.

Although the term "precision medicine" is currently new to the consumers, the concept has been a part of healthcare industry for many years. For instance, a person who requires a blood transfusion is not given blood from any random donor; instead, the blood type of donor is matched with the recipient prior transfusion to reduce the risk of complications. Although examples can be found in various areas of medicine, the role of precision medicine in everyday healthcare is relatively limited. Researchers are significantly working to expand this approach in many areas of healthcare and health in the coming years.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1085

Growth Factors

The advent of precision medicine has significantly brought a paradigm shift in the drug delivery and diagnosis of the disease. The proliferation of sequencing methodologies, particularly Next Generation Sequencing (NGS), due to the increasing cost of sequencing and development of the Human Genome Project in the field of genomics is predicted to drive the market. NGS technology provides the data related to the patients genetic makeup along with response of drugs on the patient, thereby raising the development of precision medicine for the treatment of diseases. Moreover, NGS combined with Companion Diagnostics (CDx) is analyzed to play a significant role in the advancement of personalized therapeutics and diagnostics over the forecast period. Apart from the benefits offered by the precision medicine, they are highly expensive due to the application of high-end computational methods to examine individual genes projected to hinder the market growth.

Regional Snapshots

North America dominated the global precision medicine market with revenue share of nearly 40% in 2019 and expected to grow at an escalating pace during the forecast period. Technological advancement along with the presence of major players in the region contributes significantly towards the growth of the region. However, the Asia Pacific seeks to be the most opportunistic region in the precision medicine market owing to increasing cases of cancer and other diseases along with the health awareness among people.

View Full Report with Complete ToC@ https://www.precedenceresearch.com/precision-medicine-market

Report Highlights

Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1085

Key Players & Strategies

The global precision medicine market is highly competitive owing to the presence of major market participants. These market players are highly focused towards development and innovation of personalized products to upscale their position in the market. For instance, in October 2018, Qiagen announced to launch a novel RNA-seq library preparation solution for next-generation sequencing thereby expanding its user base and portfolio significantly. Similarly, other industry participants are also working prominently for advancement and innovation in the field of precision medicine.

Some of the key players operating in the market are Biocrates Life Sciences, TepnelPharma Services, Novartis, Qiagen, Quest Diagnostics, Menarini Silicon Biosystems, NanoString Technologies, Eagle Genomics, Pfizer, Intomics, Roche, and Teva Pharmaceutical among others.

Market Segmentation

By Technology

By Application

By End-Use

By Regional Outlook

Full Report is Ready | Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1085

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 774 402 6168

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

View post:

Precision Medicine Market Poised to Grow at 11.5% By 20227 - GlobeNewswire

Fact check: mRNA vaccines kept at very cold temperatures so that they do not break apart; COVID-19 vaccines will not genetically modify humans -…

With hundreds of thousands of views social media, posts referring to Pfizer and BioNTechs COVID-19 vaccine candidate claim that any vaccine that needs to be shipped and stored at -80 degrees isnt a vaccine but rather a transfection agent, kept alive so it can infect your cells and transfer genetic material. Alleging that the vaccine will be used for genetic manipulation of humans on a massive scale, this claim is false.

Reuters Fact Check. REUTERS

The claim originated in aNov. 15 tweet from a user known as The Disruptive Physician with the handle @DocEvenhouse(here). Facebook and Instagramsharing screenshots of the tweetcan be foundhere,hereandhere.

There arecurrently threeCOVID-19 vaccinefrontrunners: one made byAstraZeneca, one made byPfizer and its German partnerBioNTech,andone made byModerna.As reportedhereby the Washington Post,AstraZeneca says that its vaccine candidate, developed by Oxford University, is up to 90% effectivein clinical trials.Pfizer andModernahavereported vaccines that are 95%effective.

The AstraZeneca vaccine uses a modified version of a chimpanzee cold virus to deliver instructions to cells to fight the target virus (here).

Meanwhile, both the Pfizer andModernacandidates rely on new technology known as messenger RNA (mRNA)to activate the immune system against the virus(here,here).Eachusessynthetic genetic materialthat can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines(here).

Each candidate has different storage temperature requirements.

TheAstraZenecavaccinecan also be transported and stored at normal fridge temperatures, which proponents say would make it easier to distribute - especially in poor countries(here).

TheModernavaccineis stored at minus20 degrees Celsius (-4F), but canbe keptfor a month atnormalrefrigerator temperatures(here).

Referencedin the social media posts, the Pfizer vaccine needs to be stored at minus 70 degrees Celsius (-94 F) or below - equivalent to an Antarctic winter(here).As reportedherebySanjay Mishra, project coordinator for the "COVID-19 andCancer Consortium" at Vanderbilt University Medical Centerand published onThe Conversation, the vaccine willdegrade in five days if keptatregularrefrigeration temperatures of slightly above freezing.

The Disruptive Physicians claim that any vaccine that needs to be shipped and stored at -80 degrees isnt a vaccine is false.AsMishraexplainshere,the biggest challenge in developing an mRNA vaccine is its inherent instability, because it is more likely to break apart above freezing temperatures.

Likening the Pfizer andModernavaccinesstoragetemperaturesto freezing food to keep it from spoiling,Margaret Liu, aboard member of theInternational Society for Vaccineswhospecializes in genetic vaccines, told NPR thatlower temperatures slow down the pace of chemical reactions,like the enzymes that break down RNA(here).Sincethemanufacturers do not disclosetheirspecific formulations, itis notyetclear whyPfizer andModernasmRNA vaccinesrequiredifferentstoragetemperatures.

Business Insider explainsherethatit is possiblePfizers vaccine could be fine at temperatures above that, but scientists were in such a rush to create the vaccine that they don't know for sure.

MRNA VACCINES DO NOT CAUSE GENETIC MANIPULATION OF HUMANS

The posts claim that the Pfizer vaccine is designed forgenetic manipulation of humans on a massive scale has no basis in fact.AsMishraclarifieshere,the synthetic genetic material contained in an mRNA vaccinedoes not mean a patients DNA is changed or passed onto their offspring.Instead, themoleculeguides the protein production inside the muscle cells, which reaches peak levels for 24 to 48 hours and can last for a few more days."

The Reuters Fact Check team previouslyfact-checked falsesocial media claims thata COVID-19 vaccineinvolving the injectionof the virussgenetic codewould genetically modify humans, visiblehere.

MarkLynas, a visiting fellow at Cornell Universitys Alliance for Science group(here),debunked the idea that such a vaccine could genetically modify an organism.Lynastold Reuters that no vaccine can genetically modify human DNA.

Thats just a myth, one often spread intentionally by anti-vaccination activists to deliberately generate confusion and mistrust, he said. Genetic modification would involve the deliberate insertion of foreign DNA into the nucleus of a human cell, and vaccines simply dont do that.

Dr. Paul McCray, Professor of Pediatrics, Microbiology, and Internal Medicine at the University of Iowa(here),previously explained to Reuters via email howaCOVID-19 vaccineusing a DNA or RNA vectorwould work:

As is the case with a vaccine that uses an inactivated (dead) virus, the only modification to the host is to stimulate them to make antibodies and T cells that will prevent infection with the virus or kill any infected cells to prevent or reduce disease severity. This is what happens if you get a virus infection naturally, but the vaccine takes the risk of serious disease out of the equation.

False. Pfizers COVID-19 vaccine candidate is stored at minus 70 degrees Celsius because of the mRNA vaccines inherent instability the very cold temperature slows down the chemical reactions that break apart RNA. Though both the Pfizer and Moderna vaccines contain synthetic genetic material, they do not genetically modify humans receiving them.

This article was produced by the Reuters Fact Check team. Read more about our work to fact-check social media postshere.

More here:

Fact check: mRNA vaccines kept at very cold temperatures so that they do not break apart; COVID-19 vaccines will not genetically modify humans -...

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying…

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced highlights from presentations being made at the American Epilepsy Society (AES) 2020 Virtual Annual Meeting December 4-8, 2020 related to the Companys work to advance STK-001, the first potential new medicine to target the underlying cause of Dravet syndrome. Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin within the first year of life. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease. Highlights from the Companys presentations include:

BUTTERFLY Observational Study Baseline Analysis

Abst. 81. Observational Study to Investigate Cognition and Quality of Life in Children and Adolescents with Dravet Syndrome: Baseline Analysis of the BUTTERFLY Study

December 5, 2020 9:00 AM 10:30 AM; Track: 4. Clinical Epilepsy / 4B. Clinical Diagnosis

22 children and adolescents with Dravet syndrome were enrolled in the Companys BUTTERFLY observational study and included in a baseline analysis.

All study participants evaluated are representative of patients with Dravet syndrome. The majority of patients were able to complete commonly used cognition assessments including either the BSID-III (Bayley Scales of Infant and Toddler Development) or the WPPSI-IV (Wechsler Preschool and Primary Scale of Intelligence Fourth Edition), indicating that these measures are valid and appropriate for use in patients with Dravet syndrome. An initial analysis of data from 17/22 patients who completed one of these assessments showed substantially decreased neurocognitive abilities compared to children of the same age level despite the use of multiple anti-epileptic therapies. The assessment also demonstrated an apparent widening in overall intellectual development that increases with age. In addition, a gap in adaptive functioning was noted using the Vineland Adaptive Behavior Scales.

We have long known that Dravet syndrome is far more than seizures and the BUTTERFLY study is providing quantifiable information on cognition and quality of life that fill gaps in our understanding of this disease and its progression as children age, said Joseph Sullivan, M.D., Professor of Neurology at UCSF Benioff Children's Hospitals and Director of the UCSF Pediatric Epilepsy Center of Excellence. Initial results from the study show significantly diminished neurocognitive abilities in children with Dravet syndrome such that 10 year-olds are functioning below the level of a healthy 1 year-old even while they are being treated with available anti-epileptic medicines. The fact that the majority of patients in this study were able to complete standard assessments of neurocognition gives us confidence that we can objectively assess whether potential new disease-modifying medicines have an effect on the non-seizure comorbidities that make Dravet so devastating.

Dravet syndrome is characterized by an array of effects that go beyond seizures and include motor and speech impairment, intellectual and developmental disabilities, behavioral deficits and abnormal sleep patterns, said Barry Ticho, M.D., Ph D., Chief Medical Officer of Stoke Therapeutics. We continue to generate strong preclinical evidence supporting the potential for STK-001 to address the underlying cause of Dravet syndrome and reduce seizure frequency. Our goal is to develop a medicine that goes beyond seizure control to address many of the other comorbidities associated with Dravet syndrome. As we look to future clinical studies of STK-001, we are encouraged by data showing the ability to diagnose children earlier as well as the validation of tools that will help us measure the potential impact of STK-001 on cognition and quality of life.

MONARCH Phase 1/2a Current Study Design

Abst. 344. Safety and Pharmacokinetics of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome: Single and Multiple Ascending Dose Design for the Open-Label Phase 1/2a MONARCH Study

December 6, 2020 12:00 PM 1:30 PM; Track: 7. Antiepileptic Drugs / 7B. Clinical Trials

A review of the study design for MONARCH, the Companys ongoing Phase 1/2a study of STK-001 in children and adolescents with Dravet syndrome will be presented during a poster session by Linda Laux, M.D., Associate Professor of Pediatrics (Neurology and Epilepsy), Northwestern University Feinberg School of Medicine. Following a recent protocol amendment, MONARCH is designed to evaluate both single and multiple ascending doses of up to 30mg of STK-001 in children and adolescents with Dravet syndrome. The primary endpoints are safety, tolerability and pharmacokinetic (PK) profile of STK-001 in Dravet syndrome patients. The impact of STK-001 on frequency of convulsive seizures and quality of life are secondary endpoints of this study. Patient enrollment and dosing in MONARCH is ongoing and preliminary safety and PK data are anticipated in 2021.

Restoration of Interneuron Firing Frequency in a Dravet Mouse Model

Abst. 236. Targeted Augmentation of Nuclear Gene Output (TANGO) of SCN1A Reduces Seizures and Rescues Parvalbumin Positive Interneuron Firing Frequency in a Mouse Model of Dravet Syndrome

December 5, 2:00 PM 3:30 PM; Platform A: Translational Research / Genetics

December 6, 12:00 PM 1:30 PM; Track: 2. Translational Research / 2B. Devices, Technologies, Stem Cells

New preclinical data provide additional evidence of the potential for TANGO antisense oligonucleotides (ASOs) to provide a gene-specific, disease-modifying treatment for Dravet syndrome. In this study, Dravet syndrome mice treated with a TANGO ASO had significantly decreased seizure frequency and increased survival. Data presented by Eric Wengert, graduate student at the University of Virginia, show that 100% of mice treated with a TANGO ASO were seizure free between postnatal day 16 and postnatal day 19 compared to 50% of vehicle-treated control mice. The data also provide evidence that decreases in seizures and mortality are, in part, due to restoration of excitability of parvalbumin (PV) expressing interneurons. PV interneurons are commonly hypoexcitable in Dravet syndrome. In this study, treatment with a TANGO ASO restored Dravet syndrome mouse PV interneuron firing frequency to that of wild-type mice.

Additional Work in a Dravet Mouse Model

Antisense Oligonucleotides Increase Scn1a Expression and Reduce Seizures and SUDEP Incidence in a Mouse Model of Dravet Syndrome

December 8, 1:30 PM 4:00 PM; Annual Fundamentals Symposium: Fundamentally New Ideas in Epilepsy Treatment and Research

Lori Isom, Ph.D., Maurice H. Seevers Professor and Chair of Pharmacology, University of Michigan Medical School, will present a review of data from experiments conducted with TANGO ASOs in a mouse model of Dravet syndrome.

Early Diagnosis of Dravet Syndrome

Abst. 392. Reducing the Time to Diagnosis and Increasing the Detection of Individuals with SCN1A-related Disease Through a Sponsored Epilepsy Genetic Testing Program

December 6, 12:00- 1:30 PM; Track: 12. Genetics / 12A. Human Studies

Data from an analysis of 6,874 children who participated in a no-cost epilepsy genetic testing program co-sponsored by Stoke showed that 152 had a positive molecular diagnosis related to the SCN1A gene, accounting for 2.2% of all patients. Results demonstrated a substantial decrease in the time to diagnosis from >6 years of age (2011-2015) to <2 years of age (2019-2020).

About STK-001

STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in a Phase 1/2a clinical trial. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. Stoke has generated preclinical data demonstrating proof-of-mechanism and proof-of-concept for STK-001. STK-001 has been granted orphan drug designation by the FDA as a potential new treatment for Dravet syndrome.

About the BUTTERFLY Observational Study

BUTTERFLY study, an ongoing, multicenter, longitudinal, prospective study of children and adolescents ages 2 to 18 who have been diagnosed with Dravet syndrome as a result of an SCN1A gene mutation. This observational study designed to evaluate neurodevelopmental status and change from baseline to 24 months. Secondary and exploratory endpoints in the study will evaluate changes in other disease measures, including seizures and additional non-seizure comorbidities. No investigational medications or other treatments will be provided. Participants continue to receive their usual care, and will be observed by a team of doctors and nurses over time for up to two years. The study is being conducted at approximately 20 sites in the United States.

About the Phase 1/2a Clinical Study (MONARCH)

The MONARCH study is a Phase 1/2a open-label study of children and adolescents ages 2 to 18 who have an established diagnosis of Dravet syndrome and have evidence of a pathogenic genetic mutation in the SCN1A gene. The primary objectives for the study will be to assess the safety and tolerability of STK-001, as well as to characterize human pharmacokinetics. A secondary objective will be to assess the efficacy as an adjunctive antiepileptic treatment with respect to the percentage change from baseline in convulsive seizure frequency over a 12-week treatment period. Stoke also intends to measure non-seizure aspects of the disease, such as quality of life, as secondary endpoints. Enrollment and dosing are ongoing in MONARCH and Stoke plans to enroll approximately 48 patients in the study across 20 sites in the United States.

Additional information about the MONARCH study can be found at https://www.monarchstudy.com/.

About Dravet Syndrome

Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures, beginning within the first year of life. Dravet syndrome is difficult to treat and has a poor long-term prognosis. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. The effects of the disease go beyond seizures and often include severe intellectual disabilities, severe developmental disabilities, motor impairment, speech impairment, autism, behavioral difficulties and sleep abnormalities. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP. Dravet syndrome affects approximately 35,000 people in the United States, Canada, Japan, Germany, France and the United Kingdom, and it is not concentrated in a particular geographic area or ethnic group.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK) is a clinical-stage biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: preclinical data and study results regarding STK-001 and Dravet syndrome, including from the BUTTERFLY study; our future operating results, financial position and liquidity; the direct and indirect impact of COVID-19 on our business, financial condition and operations, including on our expenses, supply chain, strategic partners, research and development costs, clinical trials and employees; our expectation about timing and execution of anticipated milestones, responses to regulatory authorities, expected nomination of future product candidates and timing thereof, and our ability to use study data to advance the development of STK-001; the ability of STK-001 to treat the underlying causes of Dravet syndrome; and the ability of TANGO to design medicines to increase protein production and the expected benefits thereof. These forward-looking statements may be accompanied by such words as aim, anticipate, believe, could, estimate, expect, forecast, goal, intend, may, might, plan, potential, possible, will, would, and other words and terms of similar meaning. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize STK-001, OPA1 and future product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.

Link:

Stoke Therapeutics Announces Presentations Related to the Company's Work to Advance STK-001, the First Potential New Medicine to Target the Underlying...

King George III’s illness debunked as symptom ’caused by medicine prescribed to him’ – Express

Prince Charles identifies with 'mad' King George III says expert

George III is famous for being the mad king who lost America and his erratic behaviour is well-documented. The Crown season four, released this month, has raised awareness of the Royal Family and its rocky relationship with mental health. In episode seven, Princess Margaret, played by Helena Bonham Carter, discovers that two cousins on her mothers side were sent to a hospital for people with mental disabilities, where they had no contact with the family and were even declared dead.

The Queen Mother, played by Marion Bailey explains that they did this because there were fears people would question the integrity of the bloodline if they knew there was a genetic condition in their family that affected mental faculties.

She says: The idea that one family alone has the automatic birthright to the Crown is already so hard to justify.

The gene pool of that family, it better have 100 percent purity.

There have been enough examples on the Windsor side alone for people to worry about: King George III Prince John, your uncle.

READ MORE:Queens uncle Prince Johns illness hidden from public

You add the Bowes-Lyon illness to that, the danger is it becomes untenable.

There have been numerous other references to George IIIs supposed madness, including the long-running play by Alan Bennett, The Madness of George III, which was later adapted for film starring Nigel Hawthorne in the title role.

This play and film featured a key theory as to what caused George IIIs behaviour: that he suffered from a physical, genetic blood disorder called porphyria.

Its symptoms included aches and pains, as well as the bizarre symptom of blue urine.

However, a research project based at St Georges, University of London appears to have debunked this after finding another reason for the unusual symptom.

George IIIs medical records show that the King was being given medicine based on gentian.

The plant, with its deep blue flowers, is still used today as a mild tonic, but one of the possible side effects is that it can turn urine blue.

Indeed, it seems it may not have been his condition that caused this symptom, but actually his medicine, historian Lucy Worsley explained to the BBC.

DON'T MISSPrincess Diana turned down interview with Sir David Frost[REVEALED]Meghan Markles life eerily mirrored her ex-husband Trevor Engelsons[INSIGHT]Princess Diana was traumatised by humiliating Prince Charles comment[QUOTE]

The research group concluded that George III actually did suffer from mental illness, most likely bipolar disorder.

This is based on thousands of handwritten letters written by the King that have been analysed by Dr Peter Garrard and Dr Vassiliki Rentoumi.

The academics looked at Georges use of language and discovered that during his episodes of illness, his sentences were much longer than when he was well.

A sentence containing 400 words and eight berns was not unusual.

Whats more, when the King was ill he often repeated himself and his vocabulary became more complex, creative and colourful.

All these features can be seen today in the writings and speech of patients experiencing the manic phase of illnesses such as bipolar.

People suffering from bipolar disorder experience periods of mania - or harmful euphoria, where they feel very high and overactive - followed by periods of depression, on the other end of the spectrum of mood, where they feel very low and lethargic.

George III experiencing mania would also match contemporary descriptions of his behaviour.

For example, observers spoke of his incessant loquacity and his habit of talking until the foam ran out of his mouth.

Sometimes he suffered from convulsions and his pages had to sit on him to keep him safe on the floor.

George IIIs recurring bouts of illness caused him to withdraw from daily business to recuperate out of the public eye at Kew Palace.

Later in life, it is believed he developed dementia too, and eventually in 1810, a regency was established.

See the original post here:

King George III's illness debunked as symptom 'caused by medicine prescribed to him' - Express

Following the science: the writers who have made sense of Covid – The Guardian

This year has had the makings of an epic saga: a monstrous disease that took over the world, killing the oldest, poorest and most vulnerable, imprisoning the population in lockdown and the heroic scientists who battled day and night to create a miracle vaccine to defeat it. Books are already being written about their quest, and we will rush to read them, hoping to understand more about this terrible pandemic and how it was ended.

It has been an extraordinary year to be a science writer, watching the formerly niche subjects of epidemiology, virology and immunology take centre stage a bit like how it must be for constitutional law experts when a new Brexit detail is announced. Suddenly, being a scientist and writing about science was more interesting to the public than making movies or playing football (especially when neither of these was allowed). The scramble to get a grip on this invisible global killer was all-consuming, and writers rose to the challenge, producing reams of coverage: the disease was only officially named severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) on 11 February; by June, the first book on it had been published.

To give a flavour of the initial pace of change, on 19 January, I was part of a panel reading the papers for BBC Radio 4s Broadcasting House programme, and I picked out a story in the Observer about a new Sars-like virus in China that was thought to have affected about 1,700 people. I proposed that we should take the threat of this disease seriously, but my two fellow panellists recommended healthy scepticism, saying scientists were overreacting and that they were exhausted by next plague stories. We were all about to get much more exhausted.

Fast forward a month, and I was speaking at the same literary event as a palliative care doctor and a mathematical modeller from the London School of Hygiene & Tropical Medicine, Adam Kucharski, who was giving a talk about his new book The Rules of Contagion. His presentation involved graphs showing exponential infection rates and equations explaining R values. Watching it, I felt a little pity for him it was interesting to me, especially given the UK had experienced three cases of the new coronavirus, but who else here would have the slightest interest in R values?

Well, we all know how that panned out. Just a couple of weeks later, a parent approached me in the playground as I dropped my kids off for school, chatting about the R number. Two weeks after that, the entire nation was in lockdown. Incidentally, the palliative care doctor at the event, Rachel Clarke, became, like Kucharski, a regular on news and current affairs programmes, providing valuable expertise as the R value rose and, with it, the number of deaths.

As the world shut down, the veteran infectious diseases reporter Debora MacKenzie was gearing up for the biggest assignment of her life. A longtime correspondent for New Scientist magazine, MacKenzie has covered everything from Sars to Mers to Ebola, so her finely tuned antennae picked up signals as far back as 30 December, when she noticed a post on ProMED (the Program for Monitoring Emerging Diseases), describing an outbreak of pneumonia in Wuhan. Busy hosting a full household in her French home on the outskirts of Geneva, she kept an eye out through the holidays, becoming increasingly worried. Before January was over, she had predicted the pandemic.

I was the first journalist to call it, MacKenzie says, and after that, I continued near-constant corona reporting: 14 articles by 13 March. Meanwhile, she had been contacted by the literary agent Max Edwards, who suggested she write a crash book about the pandemic, which could be published quickly. On 6 March I sent Max the pitch; on the 17th, I got the offer from Hachette, she says. MacKenzie then entered a writing frenzy, working from 7am to midnight for 45 days straight, to produce COVID-19: The Pandemic That Never Should Have Happened, and How to Stop the Next One. It coincided with lockdown in France, so my husband was doing his job from the kitchen table. And my daughter was loudly editing horror films in the room next to my office.

Just as MacKenzie was preparing to write her first book, in Washington DC the science writer Ed Yong was downing tools. He was in the middle of a 10-month sabbatical from his staff job at the Atlantic magazine to complete a popular science book about how animals sense the world around us. Id been following the news about Covid-19, through the first months of the year, with a growing unease, Yong says. I saw it spread around the world and Im a science reporter who has covered pandemics before.

By mid March, Yong could wait no more. He returned to work and quickly established himself as a leading voice on Covid. His first big article, published on 25 March, was titled How the pandemic will end. That was a 5,000-word piece that I reported and wrote in a sort of 10-day fever-dream, he says. It hit at exactly the time when people had started going into stay-at-home orders. There was so much chaos and misinformation that it seemed this was the question that everyone was asking. I got 1,000 reader emails in the space of a couple of weeks. Tens of millions of people read the piece.

Claudia Hammond, who, like all writers, had seen literary engagements cancelled, ended up working on three different BBC radio series all about the virus. Meanwhile, she says, because of lockdown, and people being furloughed, my book The Art of Rest seems to have taken on new resonance for many people.

Like Hammond, Yong and so many science journalists, I too found myself writing almost exclusively about Sars-CoV-2 from the social psychology of herd behaviour to the epidemiology of herd immunity, from genetic sequencing to spike protein targets.

For Laura Spinney, whose 2017 book about the 1918 Spanish flu pandemic, Pale Rider, anticipated the current crisis, this has been a whirlwind of a year as the book shot into bestseller lists in multiple countries, and sold new translation rights across the world. Suddenly, she had to drop her current book projects to focus solely on Covid. Its almost like the body scientific has been affected with Covid like our actual bodies have putting all its resources into this one massive problem, Spinney says. A vast amount of research has been generated this year, with a shift towards preprints and speed, and people from other specialities focusing on it because its so urgent. Thats been fascinating to watch.

This is the first digital pandemic, with people able to watch infection and death rates evolve in real time but, as Spinney points out, compared with the 1918 pandemic, we are hardly more knowledgeable about the epidemiology figures such as the infection fatality rate (IFR) partly because were still in the midst of it. We need distance from it, to collect and make sense of the data, she says. But how can we ever know how many people were infected, say, back in March, when there were no tests and even now, tests are not completely reliable? Spinney herself contracted Covid along with her husband in September, and lost her sense of smell for two weeks, although, like many, she was not tested.

Nothing brings a global pandemic into sharper focus for a writer than nearly dying from it. Broadcaster Adam Rutherford was promoting his book about racial pseudoscience, How to Argue With a Racist, in mid March, when he started to feel a bit run down and developed a cough. He called the BBC to let them know that, like his producer and several others in the Science Unit, he probably had Covid and wouldnt be coming in. The next day, during a phone interview for the Today programme, he told Martha Kearney that he expected to be over it quickly. In fact, Rutherford was gravely ill for weeks, and now suffers from long Covid.

When I was at my very worst the ambulance was called, he says. I had been remotely diagnosed with bacterial pneumonia, which had worsened because the first course of antibiotics hadnt worked. Id been given a different course, but my oxygen saturation was down to 83 you get hospitalised when it falls to 90 so the ambulance was on its way, but there was a two-hour delay I thought I was going to die.

For Rutherford, Covid-19 has been life changing, leaving him not just with enduring breathlessness and fatigue, but new insight into disability. It makes me think a lot about how there are millions of people out there with a health issue, whether its mental or physical, or a combination of the two, which is definitional something that they have to think about all the time. And it makes one more compassionate, more empathetic, because its very easy if youre healthy just to disregard people who have health complaints.

Many searched for a genetic explanation for the spread of Covid. Early on, people started talking about a genetic predisposition to infection, which if it does exist, is going to be insignificant compared to the list of known socio-economic issues, Rutherford says. We always lean towards a new sciencey artefact, such as a genetic explanation, as something that we can maybe tackle, because were not willing to do the hard thing, which is to tackle socioeconomic inequity.

The Covid pandemic has clearly been a much broader story than the science of how a virus infects us, and many of us have worked to convey the social, economic and environmental context of this global crisis. Yong describes the pandemic as an omni crisis, because it touches every aspect of our lives. It was clear from early on that to really understand it, I would need to talk to historians and sociologists, anthropologists, scholars who understand disability rather than just virologists, epidemiologists and immunologists.

Theres a reason why the countries that have fared worst with Covid are the ones led by populist leaders. A pandemic is a complex problem that affects and is a product of our human system. Populism is a denial of complexity, and populist leaders have tended to look for simple answers and to spin politically useful decisions as being based on the science.

In the US, the Trump administration openly trashed science and the nations most eminent experts. There, attitudes to Covid divided on political partisan lines, largely driven by Trump downplaying the risks. By contrast, the UK prime minister declared he was being led by the science, and appeared flanked by scientists at daily press conferences. Yet Johnsons government increasingly ignored the advice of its own scientific advisers. Worse, it exploited the public trust in scientists to push through favoured policies or excuse its actions, including the unedifying journey of Dominic Cummings, against which neither the chief scientific adviser nor chief medical officer spoke out. While many other scientists made clear their opposition to government policies, the science risked becoming increasingly politicised and co-opted by public figures with little or no scientific literacy.

There were fears of a public erosion of trust not just in government but also in scientists, just as trust was most needed. Weve seen a rise in conspiracy theories, and for every science writer rigorously explaining research findings, there has been a high-profile commentator opining against mask-wearing, denying official infection figures and spreading misinformation.

For someone like me who has written extensively about the climate crisis over the years, this all felt very familiar: the politicisation of science, the evidence-deniers and so on. Indeed many of the same financial backers and lobbyists were involved. Despite all this, public interest in science remains strong and, with the announcements of effective vaccines, white-coated lab scientists have become the heroes we all need. The tale of painstaking discovery, and the triumph of experts, has become the dominant narrative. After months of misery, there is a huge appetite for it.

In the grip of a pandemic winter, we are still a long way from delivering the happy ending, but the scientific discoveries made this year in testing, treatments and now vaccines have been a vindication of the scientific process, a story of international collaboration, selfless determination and belief in human solutions. There will be huge numbers of books written about this pandemic, studies of politics and economics, memoirs and novels. But look out for the science ones they have the power to root our drama in the workings of biology, human systems, and the scientific quest to solve a global catastrophe. And there have never been better writers to capture this extraordinary story.

Transcendence: How Humans Evolved Through Fire, Language, Beauty, and Time by Gaia Vince is out in paperback from Penguin.

By Mark Honigsbaum

Perhaps no commentator has been in greater demand this year than Adam Kucharski, a disease modeller based at the London School of Hygiene & Tropical Medicine, whose book The Rules of Contagion: Why Things Spread and Why They Stop is an accessible guide to the mathematical rules that govern the spread of infectious diseases in populations. Written before the pandemic and published in February, it makes a convincing case that just as mathematics can predict the arc of an epidemic, so it can also help us understand how social contagions, from financial panics to vaccine conspiracy theories, go viral.

In Covid-19: The Pandemic That Never Should Have Happened and How to Stop the Next One, the veteran New Scientist contributor Debora MacKenzie explains how scientists have been warning for years about the dangers posed by novel pathogens harboured by bats and other wild animals. The fault for our present predicament, she suggests, lies with politicians for failing to take the warnings seriously and not investing more in pandemic planning.

Richard Horton, editor of the Lancet, would not disagree with that verdict, but thinks that the governments scientific advisers should share the blame. In The Covid-19 Catastrophe: Whats Gone Wrong and How to Stop It Happening Again, Horton describes Britains botched response to Covid-19 as the greatest science policy failure for a generation. Scientists had all the data they needed about the threat posed by the coronavirus at the end of January, he argues, but rather than advocating for stricter measures they colluded with the government, who were keen to keep the economy ticking over.

The coronavirus is not the only animal pathogen to have leapt to humans, of course. In his influential book Spillover: Animal Infections and the Next Human Pandemic, published in 2012, David Quammen explains how the last half century or so has been marked by a succession of spillover events, from HIV and Ebola to less well-known viruses such as Hendra and Marburg. Travelling deep into the rainforest with the scientists hoping to identify the next pandemic pathogen, Quammens book is plotted like a detective thriller.

Though she is not a science journalist, Zadie Smiths essay Contempt as a Virus, which appears in her collection Intimations, captures in precise, measured prose the sense of exceptionalism and contempt for the rules exhibited by Dominic Cummings in his now infamous press conference in Downing Streets rose garden. Cleverly co-opting the language of epidemiology, Zadie quips that while back in February herd immunity had been a new concept for the people, for Cummings it was simply the seamless continuation of a long-held personal credo. Immunity. From the herd.

Mark Honigsbaum is the author of The Pandemic Century: A History of Global Contagion from the Spanish Flu to Covid-19.

Visit link:

Following the science: the writers who have made sense of Covid - The Guardian

Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain Specialty CNS Therapeutics Conference – Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the Needham Virtual Epilepsy & Pain Specialty Therapeutics Conference on Thursday, December 10, 2020, at 12:45 p.m. ET.

A live audio webcast of the fireside chat will be available on the Investors & Media section of Stokes website at https://investor.stoketherapeutics.com/. A replay of the webcast will be available for 30 days following the presentations.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a clinical-stage biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

More here:

Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain Specialty CNS Therapeutics Conference - Business Wire

Gambling: Take the over on the Chiefs winning vs. the Broncos and receivers faring well – Colorado Springs Gazette

Denver Broncos (4-7) at Kansas City Chiefs (10-1)

Money line: Broncos +695 (BetMGM), Chiefs -900 (FanDuel)

Spread: Chiefs - 13.5

Total: 51

The NFL didnt do the Denver Broncos any favors last week, and now the schedule isnt on their side as they have to travel to Arrowhead Stadium to take on the Kansas City Chiefs on Sunday. At least theyre expected to have Drew Lock back under center as he missed last week after failing to follow proper COVID-19 mask protocols.

The Broncos were forced to play practice-squad wide receiver Kendall Hinton at quarterback in Week 12 against the New Orleans Saints, and he was only able to complete one of his nine passes. He finished with two interceptions and 13 passing yards in the 31-3 loss. It was Denvers third loss in its past four games, putting a huge dent in its playoff hopes when you consider the matchup this week against the Chiefs, who have won six straight games.

The weather for the rematch wont be as bad as the Week 7 matchup in Denver, which saw the Broncos fall 43-16 to the Chiefs. Nonetheless, its a very tough task for the defense as Tyreek Hill and Travis Kelce are two and three respectively in receiving yards, and theyve combined to score 20 touchdowns. Hill leads the NFL with 13 touchdowns as hes racked up nine over a five-game TD streak. He has a ridiculous 582 yards in his past four games (269 last week).

All Patrick Mahomes has done over his last four games is throw for 14 touchdowns. He has at least 348 yards in each of those four games and he leads the NFL with 3,497 passing yards. Hes third in touchdowns with 30 and hes only been picked off twice.

The backdoor cover is always in play with big spreads like this, but Denver will need Locks best effort. The Broncos QB has thrown 11 interceptions over his past six games and he has three in two games against the Chiefs, with zero passing touchdowns.

KC enters Week 13 with the highest implied team total (32.5), while the Broncos have the fourth-lowest at 18.5. Kansas City ranks first in time of possession and theyre the No. 1 team on third down. The Broncos, on the other hand, rank 26th in time of possession and third-to-last in third-down rate.

Prediction: 34-14, Kansas City

Tyreek Hill OVER 73.5 Receiving Yards -110 (FanDuel) and OVER 5.5 Receptions -120 (BetMGM)

Hill is on too big of a roll to not take a shot on his yardage prop. As mentioned, hes second in the NFL in receiving yards and hes averaging 145.5 per game over his last four contests. The Chiefs havent had a lot of success running the football lately, which has resulted in 42-plus pass attempts for Mahomes in each of his past four games.

Tim Patrick OVER 3.5 Receptions, +100 (DraftKings)

Forget last week, as Patrick only received two targets from Hinton. The Broncos wideout had 23 targets and 13 catches in his three games prior to last week. Hes the big-threat play in Denvers offense and Lock will have to throw the ball to keep pace. All we need is four grabs from Patrick and the return is pretty solid. Its a number hes had in six of his past seven games (not counting last week).

Read more from the original source:

Gambling: Take the over on the Chiefs winning vs. the Broncos and receivers faring well - Colorado Springs Gazette

Features of Gambling Regulation in the Different States of America – South Florida Reporter

The United States continues to present, implement, and overturn gambling laws as the industry grows. The relationship between gambling and society has been influenced by perception, history, religion, and economic principles. Since these aspects vary from one state to the next, law, especially those determined by the living conditions and the demographics in a particular state, you will find different laws.

Thus, while one state is legalizing gaming and creating bodies to oversee their operations, others like Hawaii do not welcome any form of betting. The latter is extreme because if you have a social activity, you need to ensure that none of the participants is gaining from it; otherwise, your action is illegal.

While all these states have different perspectives on gambling and what it means for the community, the regulatory laws focus on several aspects. Whether it is legal or illegal in a state has multiple answers, depending on where you are. Some do not condone any form of betting, while others that state gaming is illegal will allow lottery and bingo games. Since these are also forms of gaming, the question begs what defines legality.

In such cases, the morality of gambling comes to play, and it is more a matter of why people gamble and who benefits. This is reflective of a historical period when the colonizers allowed gambling to facilitate the building of towns. People in strict parts of the country that dont have these alternative options have to travel out of state to get a little excitement.

With the growing online betting industry, some people in states that term gambling illegal can access online casinos. However, this is also frowned upon. Very few have legalized online gambling. There have been attempts to establish a gambling enforcement act for online gambling. While it is easy to keep track of land-based casinos, the online world proves a little more problematic.

This is because of the unlimited access to casinos. Numerous reviews make it easy for players to find an ideal platform. You will need to define your gambling needs, and this will help you find the right casino. There are numerous options for a $10 deposit casino, so make sure you look at all aspects. Then, all you need to do is register and create an account. Once you have made your first deposit, you can start playing. Casinos offer a different number on the minimum you can start playing with $10.

Some states have legalized online gambling, while others have not. However, players from all can access games from international casinos with licensing from others. Nevada is one of the most famous gambling states. With Las Vegas, one of the biggest gambling cities in the world, this state is a little more liberal with games of chance than many others.

Although Nevada has been a gambling state for a long time in history, it was mostly run by organized crime members. As such, to reclaim the gambling industry and separate the activity from the criminals, the state established the Nevada Gaming Board. This body was tasked with regulating and breaking all ties with organized crime.

The governments established the rule that it was illegal to send money across state lines for the purpose of gambling. This law is foundational in implementing rules on online gambling.

Another aspect of gambling that varies from one state to the next is that of age. While the overall idea is that only people over the age of 21 should gamble. Some states are more flexible with the implementation. In some, you can play bingo and participate in the lottery from the age of 18.

The US has several conversations that will never receive a one-size-fits-all solution. As such, it is impossible to conclude what is next for all. However, with the growing online industry, the regulatory laws in place will not be as effective as possible. Like the sports protection act that had banned all sports betting, time might prove the need to overturn the regulation. This is mostly informed by the fact that it is impossible to control access to online casinos.

Another major motivator for legalizing casino gambling is the revenue. In 2018, the US earned more than 10.5 billion in revenue from gambling online and in brick and motor casinos. This is the same year that the district of Columbia made sports gambling legal. This financial motivation has been part of history for many states that eventually overturned laws banning gambling, which led to the establishment of Las Vegas and Atlantic City.

Some states that dont have a definite stance on legal online gambling or illegal gambling often have loopholes. For instance, states that have casinos on tribal land have other establishments that offer these services. Although the US has liberal laws on betting, not all states are that liberated.

See the original post:

Features of Gambling Regulation in the Different States of America - South Florida Reporter

Preventing problem gambling this holiday season | Community – The News Guard

Celebrations look different this year as we make changes to keep our families and communities safe.

In addition to preventing illness, there are ways to help prevent loved ones from developing a gambling problem. Similar to substance use, gambling carries risk. Breaks from school and work provide opportunities to check in on your loved ones about their gambling activities and to talk with youth about the risks of gambling. A change in someones behavior or an increase in their gambling are both warning signs of problem gambling.

Gambling in youth is linked with other risks factors for youth. Oregon 11th graders that reported participating in gambling activities also had higher rates of skipping school, being in a physical fight, being sad for two or more weeks, and using alcohol, marijuana, or other drugs. Parents or caretakers talking about the risk of gambling with teens can increase their perception of risk and can reduce their risky behaviors.

For adults that choose to gamble, you can reduce your risk of developing a gambling problem by using the following guidelines:

Dont gamble on credit or borrowed money

Dont gamble to win back lost money (also known as chasing losses)

Dont gamble to cope with negative feeling or to escape

Dont let gambling be your only social or recreational activity

Dont let youth gamble

Seek help if gambling becomes a problem for you or a loved one

In Oregon, problem gambling treatment is free and confidential. Treatment and support are available to anyone with a gambling disorder and anyone affected by someones gambling. For support and resources call or visit:

The Lincoln County Problem Gambling Treatment Program (541) 265-4196 (Mon-Fri 8 a.m. - 5 p.m.)

Oregon Problem Gambling Resource at 1-877-My-Limit or OPGR.org (available 24 hours a day)

Lincoln County Public Health, in collaboration with our community partners, provides leadership to assure the conditions for healthy communities.

View post:

Preventing problem gambling this holiday season | Community - The News Guard

Ladies, place your bets Online gambling on the rise across Africa – The Southern Times

Johanesburg - Online sports betting has seen the gambling industry growing steadily across Africa, and governments are scrambling to catch up on the regulatory front.

Head of Statistics the University of Venda in South Africa, Dr Alphonce Bere, tells The Southern Times that the proliferation of smartphones and aggressive marketing by betting companies has seen increasingly more people gambling online, with wagers on sporting events the firm favourite of punters.

Sports betting is more popular today in the continent than it was two years ago. Most African punters have user accounts on international online betting platforms that have operations in numerous jurisdictions.

Currently, sports betting in Africa mainly features bets on football and horse racing. There is a lot of interest in horse racing in North Africa that dates back to the 15th century. Africans have been betting on football for more than 70 years now, Dr Bere says.

He adds that in 2018, the gambling and gaming industry in Kenya, Nigeria and South Africa reached US$40 billion. His research shows that around 60 million Nigerians aged between 18 and 40 in a country of around 150 million people - participate in different forms of sports betting, with the average wager per person at US$15 daily.

Unlike other African countries, South Africa has properly regulated gambling. The gambling laws are not very tough but tolerant for South Africans. The lenient laws have allowed international online sports betting companies to offer their services.

Unemployment has also contributed immensely to the rise of betting as people take on the odds to make a living.

The unemployment rate is very high in Africa. With the entry of foreign and local betting companies, youths engage in online sports betting for an opportunity to win big money. Unlike in developed countries, here you can make wagers with as little as US$1, or even less. That makes the playground more suitable for unemployed people.

According to studies by the South African government, over 50 percent of adults place sports bets online frequently.

Dr Bere said that the convenience of mobile money had advanced the march of gambling.

And with so many Africans keen on sports on TV, thanks to satellite television and growing Internet penetration, it is no great wonder that a lot bets are placed on football.

See original here:

Ladies, place your bets Online gambling on the rise across Africa - The Southern Times

There is good and bad to states allowing gambling – Norfolk Daily News

Nebraskans have the chance to gamble in casinos. It is now legal to gamble in little ole Nebraska.

Before you haul yourself off to the nearest casino, there are some very important questions to be answered. Specifically, the big question everyone first thinks of when thinking about gambling; is gambling a good idea, or a bad one?

I myself wondered what the answer to this question was when the recent law was passed, so I decided to research it. While I originally thought that the answer was clear, it turns out, the answer, like life, isnt just black and white.

In the article Gambling: a Controlled Substance, William Thompson discusses how gambling, while good in some aspects, is also bad in other aspects, especially unregulated. Thompson explains that in governments that dont oversee gambling, most people dont have issues with gambling. He then, however, states But another 20% overindulge. They incur debts. Four percent cannot stop without the intervention of others. Then there are the 0.5-1% (and these are conservative estimates) who fall into destructive behaviors.

Families are destroyed, friendships broken, employment disrupted. Cycles of deception and crime lead to ruined lives and in many cases, suicide. He describes gambling as a drug and shows that gambling can be very destructive and unregulated.

While the states how gambling can be harmful, he also shows how gambling can be positive, saying that he does not oppose all gambling. He lives in Las Vegas, a city notorious for economic benefits from gambling. He said his community has the fastest growing economy in the country thanks to gambling, and states Gambling provides most of the tax revenues that support our public services. Gambling is responsible for over 60% of our jobs. With William Thompsons article Gambling: a Controlled Substance, it is easy to see how gambling has two sides, much like a coin.

What I learned from my research is that there is no 100% right answer; gambling is harmful and beneficial. In short, while gambling is beneficial to the economy, it can be harmful to people when unregulated. I believe that if gambling is well regulated, then it will be a positive thing. The concern is the people who become addicted to it, which is where I think regulations will help out. Gambling is fun and good for the economy. As long as it is regulated in a way where people who have trouble stopping get help and/or are stopped, I believe that this will be a good thing for Nebraska. Who knows? Maybe when I am old enough to gamble, Ill be the next big jackpot winner. I can only dream.

The rest is here:

There is good and bad to states allowing gambling - Norfolk Daily News

Football can’t take the easy route and ignore its gambling problem – The Drum

As the UK government puts betting advertising under the microscope, the English Football League has leaped to the defence of the bookies, highlighting the importance of their sponsorships to clubs in the wake of ongoing financial troubles. Ged Colleypriest, founder of Underdog Sports Marketing, examines if football can cope with having the punting pound removed from its economy.

Much has been spoken about the responsible gambling messaging that has become more prominent since scrutiny was stepped up. SkyBet, which sponsors the EFL for example, displays messages such as Set a Deposit Limit on the sleeve badges of players in its leagues. This is, of course, a positive step, but can it really work? One need only look at Formula 1 for a word of warning. Footballs relationship with the bookies is akin to that of F1 and tobacco. While F1 banned smoking sponsors logos in 2006, the presence of big tobacco firms lingers like the smell of cigarettes on a favourite smoking jacket.

Firms like Phillip Morris replaces the Marlboro logo on the Ferraris they sponsor with slogans such as Mission Winnow. McClaren and British American Tobacco have a similar arrangement with Building a Better Tomorrow. This being their movement to create a smoke-free world, or, to put it plainly, to sell vaping products. This circumvents the F1 ban because it is not a smoked product, it still however, keeps the company at the front of mind. Of course, the tobacco firms still make huge profits through traditional products.

If football allows gambling to stay by pedalling its gamble responsibly mottos, it is in danger of making the same mistake.

Never waste a good crisis or words to that effect have been attributed to Winston Churchill. Well, its safe to say that football, specifically many of the EFL clubs, have been trying to navigate a financial crisis for some time. Bailout talks remain complicated but are in a better position than they were a month ago.

Throughout these talks, unsurprisingly, the EFL has been quick to defend the financial support that bookmakers bring. Describing their backing as important now as its ever been. This is not in doubt. Even if there is a bail-out, the 40m a season that bookies generate for the league and clubs is going to be required to weather the storm. But football is in need of complete reform. For all the talk of sustainability, as the Saving the Beautiful Game manifesto points out, too many clubs and owners have been guilty of spending hard and gambling (for want of a better word) on short term success to get the pot of gold that the Premier League brings. There is a huge danger that if the game doesnt cease this opportunity to sever its ties with bookmaking firms, then it never will.

Just because bookmaking money is there, doesnt mean its the only option. Clubs like Luton Town have a policy of not working with gambling firms because of the potential harm that could cause their fans.

The plight of Bury, Wigan, Macclesfield and numerous others have been heartbreaking for their fans. Pulling the rug from the carpet and banning betting sponsorship immediately would increase the risk of this happening to more teams. But a phased approach that allows a period of grace for clubs and governing bodies to get their house in order, is something that could work. Premier League clubs have the least reliance on bookmakers with the vast majority of their income coming from broadcast rights. Plus, it commands the most viewers, so provides bookie sponsors with the most exposure. Therefore, starting with the top-flight would be the most logical approach. The EFL could follow but be allowed more time in order to secure sponsors from other sectors.

Putting aside the moral issue, something else Covid-19 has demonstrated is the reliance on bookmaking as a category. There are more bookies than you can even imagine and nearly all of them are prepared to buy sponsorships from clubs. Many clubs are happy to take the bookie money, because its easier than looking outside the category. Which is understandable when you have a sales target over your head.

But what it doesnt do is future-proof your club as a business. If you continue to do the same style of sponsorship, largely badging exercises, just alternating which bookmaker is on your shirt, you leave yourself massively exposed when that sector dries up or is taken away. There arent many categories that are prepared to hand over money as easily as the bookies, so its going to be a much harder fix.

But this is where the good news comes in. There are some wonderful examples out there of small football teams showing outstanding creative thinking to attract sponsors that are in theory out of their league. Take Stevenage, for example. Its sponsorship with Burger King has attracted a huge amount of adulation. The team was the lowest ranked team in FIFA 20, so the club and sponsor launched the Stevenage Challenge encouraging gamers to play as The Boro. The results were outstanding as the club became the most chosen team in Career Mode resulting in loads of exposure and genuine engagement for Burger King.

Likewise, Forest Green Rovers is hardly a household name in world football. But its profile is constantly rising because of the story it tells off the pitch. The team became the worlds first vegan club in 2015 and the first to be certified carbon neutral in 2018. So, while it may still be in the bottom tier of the EFL, the team attracted investment from Arsenal star Hector Bellerin and secured a naming rights deal with Innocent.

These arent easy fixes, but more inspiration for how smaller teams can and must move away from the traditional model of sponsorship, that largely involves placing a brands logo (usually a bookies) on a shirt and hoping for the best.

The Department for Culture, Media and Sport review is expected to be revealed in early 2021 and changes in regulation could be in place for the 2021/2022 season. So clubs and governing bodies dont have long to wait or to plan for the future. The changes could have a seismic impact on the sport for fans, clubs and financial directors alike. All of which means its essential that clubs start planning for a future that is different from what weve known since regulations were relaxed in 2007. But as the likes of Luton, Forest Green, Stevenage and others have shown, there is a life outside of bookmaking sponsorship but it requires a different way of thinking.

Ged Colleypriest is founder of Underdog Sports Marketing.

// Featured in this article

Underdog Sports Marketing

Are you looking to market your brand or product to sports fans? Underdog Sports Marketing is here to help. We are experts in social media, video content and fans. We exist to help both brands and righ...

See the article here:

Football can't take the easy route and ignore its gambling problem - The Drum